A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of OPC-6535 (tetomilast) and to determine its optimal dose by once-daily oral administration at 0, 12.5, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic acid (5-ASA) in patients with active ulcerative colitis.

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04989907` - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Completed	`NCT03494764` - Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares	Phase 2
Recruiting	`NCT03937609` - TITRATE (inducTIon for acuTe ulceRATivE Colitis)	Phase 4
Completed	`NCT00503243` - Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis	Phase 3
Completed	`NCT03606499` - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed	`NCT02537210` - Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis	N/A
Active, not recruiting	`NCT02316678` - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics	N/A
Completed	`NCT00488631` - An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT00928681` - A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis	Phase 1
Recruiting	`NCT05242484` - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT01036022` - Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis	Phase 2
Recruiting	`NCT03841045` - Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
Active, not recruiting	`NCT05528510` - A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT02825914` - CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)	N/A
Recruiting	`NCT06049017` - A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT04567628` - Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
Withdrawn	`NCT05999708` - A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants	Phase 1
Recruiting	`NCT05611671` - A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC	Phase 2
Active, not recruiting	`NCT03596645` - A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT03648541` - BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis	Phase 2

NCT number	NCT00317356
Study type	Interventional
Source	Otsuka Pharmaceutical Co., Ltd.
Contact
Status	Terminated
Phase	Phase 2
Start date	May 2006
Completion date	August 2007

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms